INMB – inmune bio inc. - common stock (US:NASDAQ)
Stock Stats
News
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
INmune Bio (INMB) was upgraded by Lucid Cap Mkts from "hold" to "strong-buy".
INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript [Seeking Alpha]
INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript [Seeking Alpha]
Form 8-K Inmune Bio, Inc. For: Feb 27
Form 8-K Inmune Bio, Inc. For: Feb 23
Form 8-K Inmune Bio, Inc. For: Feb 19
Form 8-K Inmune Bio, Inc. For: Feb 10
Form 8-K Inmune Bio, Inc. For: Jan 27
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.